Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for Acute Migraine Attack
NCT04152083Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Nov 2019
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Eptinezumab with Placebo (2 arms). Primary endpoints: Time to Headache Pain Freedom and Time to Absence of Most Bothersome Symptom (MBS). Started Nov 2019; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04152083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152083.